Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of metastases
At least one measurable metastatic lesion (as per RECIST criteria)
Life expectancy of \> 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Adequate hematological, renal and liver function
You may not be if
Prior chemotherapy for metastatic disease
Clinically significant cardiovascular disease
Ongoing treatment with aspirin (325 mg/day) or other medications known to predispose for gastrointestinal ulceration
Participation in an investigational trial in the previous 3 months
Pregnant or lactating women
History of thrombotic or haemorrhagic disorders
Evidence of bleeding diathesis or coagulopathy
Uncontrolled hypertension
Known hypersensitivity to Avastin and any of its excipients, or any of the chemotherapies
Evidence of any disease or disorder that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
Clareo Health | An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum
